Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Human B cells fail to secrete type I interferons upon cytoplasmic DNA exposure.

Gram AM, Sun C, Landman SL, Oosenbrug T, Koppejan HJ, Kwakkenbos MJ, Hoeben RC, Paludan SR, Ressing ME.

Mol Immunol. 2017 Nov;91:225-237. doi: 10.1016/j.molimm.2017.08.025. Epub 2017 Sep 30.

2.

Chemical Tools for Studying TLR Signaling Dynamics.

Oosenbrug T, van de Graaff MJ, Ressing ME, van Kasteren SI.

Cell Chem Biol. 2017 Jul 20;24(7):801-812. doi: 10.1016/j.chembiol.2017.05.022. Epub 2017 Jun 22. Review.

3.

EBV MicroRNA BART16 Suppresses Type I IFN Signaling.

Hooykaas MJG, van Gent M, Soppe JA, Kruse E, Boer IGJ, van Leenen D, Groot Koerkamp MJA, Holstege FCP, Ressing ME, Wiertz EJHJ, Lebbink RJ.

J Immunol. 2017 May 15;198(10):4062-4073. doi: 10.4049/jimmunol.1501605. Epub 2017 Apr 17.

4.

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.

PLoS Pathog. 2016 Apr 14;12(4):e1005550. doi: 10.1371/journal.ppat.1005550. eCollection 2016 Apr.

5.

Immune Evasion by Epstein-Barr Virus.

Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ.

Curr Top Microbiol Immunol. 2015;391:355-81. doi: 10.1007/978-3-319-22834-1_12. Review.

PMID:
26428381
6.

Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution.

Verweij MC, Horst D, Griffin BD, Luteijn RD, Davison AJ, Ressing ME, Wiertz EJ.

PLoS Pathog. 2015 Apr 16;11(4):e1004743. doi: 10.1371/journal.ppat.1004743. eCollection 2015 Apr. Review.

7.

Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion.

van Gent M, Gram AM, Boer IG, Geerdink RJ, Lindenbergh MF, Lebbink RJ, Wiertz EJ, Ressing ME.

J Gen Virol. 2015 Apr;96(Pt 4):858-65. doi: 10.1099/jgv.0.000021. Epub 2014 Dec 12.

PMID:
25502648
8.

Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAP.

Luteijn RD, Hoelen H, Kruse E, van Leeuwen WF, Grootens J, Horst D, Koorengevel M, Drijfhout JW, Kremmer E, Früh K, Neefjes JJ, Killian A, Lebbink RJ, Ressing ME, Wiertz EJ.

J Immunol. 2014 Aug 15;193(4):1578-89. doi: 10.4049/jimmunol.1400964. Epub 2014 Jul 14.

9.

A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation.

van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, Kremmer E, Hoeben RC, LeProust EM, Chen S, Hoelen H, Ressing ME, Patena W, Weissman JS, McManus MT, Wiertz EJ, Lebbink RJ.

Nat Commun. 2014 May 8;5:3832. doi: 10.1038/ncomms4832.

10.

Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.

van Gent M, Braem SG, de Jong A, Delagic N, Peeters JG, Boer IG, Moynagh PN, Kremmer E, Wiertz EJ, Ovaa H, Griffin BD, Ressing ME.

PLoS Pathog. 2014 Feb 20;10(2):e1003960. doi: 10.1371/journal.ppat.1003960. eCollection 2014 Feb.

11.

Evaluation of viral interference with MHC class I-restricted antigen processing and presentation using a flow cytometry-based approach.

Horst D, Ressing ME, Mulder A, Wiertz EJHJ.

Methods Mol Biol. 2013;960:127-136. doi: 10.1007/978-1-62703-218-6_10.

PMID:
23329483
12.

EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.

Griffin BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, Wang F, Ressing ME, Wiertz E.

J Immunol. 2013 Feb 15;190(4):1672-84. doi: 10.4049/jimmunol.1102462. Epub 2013 Jan 11.

13.

Hiding lipid presentation: viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation.

Horst D, Geerdink RJ, Gram AM, Stoppelenburg AJ, Ressing ME.

Viruses. 2012 Oct 23;4(10):2379-99. doi: 10.3390/v4102379. Review.

14.

Viral interference with antigen presentation: trapping TAP.

Ressing ME, Luteijn RD, Horst D, Wiertz EJ.

Mol Immunol. 2013 Sep;55(2):139-42. doi: 10.1016/j.molimm.2012.10.009. Epub 2012 Nov 8. Review.

PMID:
23141382
15.

Inflammasomes and viruses: cellular defence versus viral offence.

Gram AM, Frenkel J, Ressing ME.

J Gen Virol. 2012 Oct;93(Pt 10):2063-75. doi: 10.1099/vir.0.042978-0. Epub 2012 Jun 27. Review.

PMID:
22739062
16.

The "Bridge" in the Epstein-Barr virus alkaline exonuclease protein BGLF5 contributes to shutoff activity during productive infection.

Horst D, Burmeister WP, Boer IG, van Leeuwen D, Buisson M, Gorbalenya AE, Wiertz EJ, Ressing ME.

J Virol. 2012 Sep;86(17):9175-87. doi: 10.1128/JVI.00309-12. Epub 2012 Jun 13.

17.

CD200 receptor controls sex-specific TLR7 responses to viral infection.

Karnam G, Rygiel TP, Raaben M, Grinwis GC, Coenjaerts FE, Ressing ME, Rottier PJ, de Haan CA, Meyaard L.

PLoS Pathog. 2012;8(5):e1002710. doi: 10.1371/journal.ppat.1002710. Epub 2012 May 17.

18.

Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.

Horst D, Burrows SR, Gatherer D, van Wilgenburg B, Bell MJ, Boer IG, Ressing ME, Wiertz EJ.

J Virol. 2012 Jan;86(1):572-7. doi: 10.1128/JVI.05151-11. Epub 2011 Oct 19.

19.

Structural and functional analysis of the TAP-inhibiting UL49.5 proteins of varicelloviruses.

Verweij MC, Lipińska AD, Koppers-Lalic D, Quinten E, Funke J, van Leeuwen HC, Bieńkowska-Szewczyk K, Koch J, Ressing ME, Wiertz EJ.

Mol Immunol. 2011 Sep;48(15-16):2038-51. doi: 10.1016/j.molimm.2011.06.438. Epub 2011 Jul 20.

PMID:
21764135
20.

Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.

Horst D, Ressing ME, Wiertz EJ.

Immunol Cell Biol. 2011 Mar;89(3):359-66. doi: 10.1038/icb.2010.129. Epub 2011 Feb 8. Review.

PMID:
21301483
21.

EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.

Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ.

J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.

22.

Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses.

Verweij MC, Ressing ME, Knetsch W, Quinten E, Halenius A, van Bel N, Hengel H, Drijfhout JW, van Hall T, Wiertz EJ.

Mol Immunol. 2011 Mar;48(6-7):835-45. doi: 10.1016/j.molimm.2010.12.008. Epub 2011 Feb 2.

23.

EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME.

J Immunol. 2011 Feb 1;186(3):1694-702. doi: 10.4049/jimmunol.0903120. Epub 2010 Dec 29.

24.

The capacity of UL49.5 proteins to inhibit TAP is widely distributed among members of the genus Varicellovirus.

Verweij MC, Lipinska AD, Koppers-Lalic D, van Leeuwen WF, Cohen JI, Kinchington PR, Messaoudi I, Bienkowska-Szewczyk K, Ressing ME, Rijsewijk FA, Wiertz EJ.

J Virol. 2011 Mar;85(5):2351-63. doi: 10.1128/JVI.01621-10. Epub 2010 Dec 15.

25.

Viral evasion of T cell immunity: ancient mechanisms offering new applications.

Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ.

Curr Opin Immunol. 2011 Feb;23(1):96-103. doi: 10.1016/j.coi.2010.11.005. Epub 2010 Dec 9. Review.

26.

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM.

Cancer Immunol Immunother. 2010 Dec;59(12):1825-38. doi: 10.1007/s00262-010-0908-z. Epub 2010 Sep 5.

27.

Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.

Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.

PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26.

28.

A bridge crosses the active-site canyon of the Epstein-Barr virus nuclease with DNase and RNase activities.

Buisson M, Géoui T, Flot D, Tarbouriech N, Ressing ME, Wiertz EJ, Burmeister WP.

J Mol Biol. 2009 Aug 28;391(4):717-28. doi: 10.1016/j.jmb.2009.06.034. Epub 2009 Jun 16.

PMID:
19538972
29.

Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.

Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME.

J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218.

30.

The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.

Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, Wiertz EJ, Rowe M.

PLoS Pathog. 2009 Jan;5(1):e1000255. doi: 10.1371/journal.ppat.1000255. Epub 2009 Jan 2.

31.

Manipulation of the immune response by Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus: consequences for tumor development.

Ressing ME, Wiertz EJ.

Semin Cancer Biol. 2008 Dec;18(6):379-80. doi: 10.1016/j.semcancer.2008.10.010. Epub 2008 Oct 31. No abstract available.

PMID:
18992819
32.

Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.

Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ.

Semin Cancer Biol. 2008 Dec;18(6):397-408. doi: 10.1016/j.semcancer.2008.10.008. Epub 2008 Oct 25. Review.

PMID:
18977445
33.

The varicellovirus UL49.5 protein blocks the transporter associated with antigen processing (TAP) by inhibiting essential conformational transitions in the 6+6 transmembrane TAP core complex.

Verweij MC, Koppers-Lalic D, Loch S, Klauschies F, de la Salle H, Quinten E, Lehner PJ, Mulder A, Knittler MR, Tampé R, Koch J, Ressing ME, Wiertz EJ.

J Immunol. 2008 Oct 1;181(7):4894-907.

34.

Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP.

Koppers-Lalic D, Verweij MC, Lipińska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Marcondes Rezende M, Daus F, Bieńkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampé R, Neefjes JJ, Chowdhury SI, Ressing ME, Rijsewijk FA, Wiertz EJ.

PLoS Pathog. 2008 May 30;4(5):e1000080. doi: 10.1371/journal.ppat.1000080.

35.

The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function.

Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, Ressing ME, Rowe M.

J Virol. 2008 Mar;82(5):2385-93. Epub 2007 Dec 19.

36.

TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes.

Oosten LE, Koppers-Lalic D, Blokland E, Mulder A, Ressing ME, Mutis T, van Halteren AG, Wiertz EJ, Goulmy E.

Int Immunol. 2007 Sep;19(9):1115-22.

PMID:
17855435
37.

A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.

Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ.

J Exp Med. 2007 Aug 6;204(8):1863-73. Epub 2007 Jul 9.

38.

The nested open reading frame in the Epstein-Barr virus nuclear antigen-1 mRNA encodes a protein capable of inhibiting antigen presentation in cis.

Ossevoort M, Zaldumbide A, te Velthuis AJ, Melchers M, Ressing ME, Wiertz EJ, Hoeben RC.

Mol Immunol. 2007 Jul;44(14):3588-96. Epub 2007 Apr 20.

PMID:
17449101
39.

Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion.

Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, Ganem D, Middeldorp J, Wiertz EJ, Ressing ME.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3366-71. Epub 2007 Feb 21.

40.

Adenovirus-specific CD4+ T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction.

Heemskerk B, van Vreeswijk T, Veltrop-Duits LA, Sombroek CC, Franken K, Verhoosel RM, Hiemstra PS, van Leeuwen D, Ressing ME, Toes RE, van Tol MJ, Schilham MW.

J Immunol. 2006 Dec 15;177(12):8851-9.

41.

Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Wiertz EJ, Devlin R, Collins HL, Ressing ME.

J Virol. 2007 May;81(9):4389-96. Epub 2006 Nov 1. Review. No abstract available.

42.

Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.

Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, Wiertz EJ, Rowe M.

J Immunol. 2005 Jun 1;174(11):6829-38.

43.

Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing.

Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J, Marcondes Rezende M, Admiraal P, van Leeuwen D, Bienkowska-Szewczyk K, Mettenleiter TC, Rijsewijk FA, Tampé R, Neefjes J, Wiertz EJ.

Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5144-9. Epub 2005 Mar 25.

44.

Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Ressing ME, van Leeuwen D, Verreck FA, Keating S, Gomez R, Franken KL, Ottenhoff TH, Spriggs M, Schumacher TN, Hutt-Fletcher LM, Rowe M, Wiertz EJ.

J Virol. 2005 Jan;79(2):841-52.

45.

Bovine herpesvirus 1 interferes with TAP-dependent peptide transport and intracellular trafficking of MHC class I molecules in human cells.

Koppers-Lalic D, Rychlowski M, van Leeuwen D, Rijsewijk FA, Ressing ME, Neefjes JJ, Bienkowska-Szewczyk K, Wiertz EJ.

Arch Virol. 2003 Oct;148(10):2023-37.

PMID:
14551822
46.

Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Ressing ME, van Leeuwen D, Verreck FA, Gomez R, Heemskerk B, Toebes M, Mullen MM, Jardetzky TS, Longnecker R, Schilham MW, Ottenhoff TH, Neefjes J, Schumacher TN, Hutt-Fletcher LM, Wiertz EJ.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11583-8. Epub 2003 Sep 22.

47.

The UL41-encoded virion host shutoff (vhs) protein and vhs-independent mechanisms are responsible for down-regulation of MHC class I molecules by bovine herpesvirus 1.

Koppers-Lalic D, Rijsewijk FA, Verschuren SB, van Gaans-Van den Brink JA, Neisig A, Ressing ME, Neefjes J, Wiertz EJ.

J Gen Virol. 2001 Sep;82(Pt 9):2071-81.

PMID:
11514716
48.

Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.

van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R.

Int J Cancer. 2001 Mar 1;91(5):612-8.

49.

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ.

J Immunother. 2000 Mar-Apr;23(2):255-66.

PMID:
10746552
50.

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.

van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB.

Eur J Cancer. 1999 Jun;35(6):946-52.

PMID:
10533477

Supplemental Content

Loading ...
Support Center